Radiolife

What Radiolife does

Radiolife is a Wilmington, Delaware-based healthcare diagnostics company founded in 2021 that has developed a proprietary platform combining Radiofrequency (RF) sensing with artificial intelligence to enable rapid, point-of-care disease detection. The company's core product, Cube Scan, is positioned as an investigational diagnostic medical device that the company claims can deliver results in seconds — for example, a Covid-19 diagnosis in 10 seconds — and is targeted at hospitals, clinics, research organizations, and underserved communities globally. A veterinary variant, Cube Scan Vet, extends the same RF + AI platform to animal health, including a real-time viral detection system for HPAI (H5N1 avian influenza) monitoring in poultry that was showcased at the Agricultural Outlook Forum.

The underlying technology pairs a proprietary RF sensor with AI-driven signal analysis to generate diagnostic outputs, supported by a granted patent on the diagnostic medical device. The business model is anchored on hardware sales of the Cube Scan and Cube Scan Vet devices, with prospective revenue from technology licensing and a modest $10/month newsletter subscription. The go-to-market combines enterprise field sales to healthcare institutions with partnership-driven access to research organizations, ecosystem accelerators (The Roux Institute at Northeastern University, NVIDIA Inception, Hello Tomorrow Deep-Tech Pioneers), and event-led visibility (BioTech Unicorn Battle). The company has 1-10 employees and is led by CEO and founder Sergio Schirmer alongside co-founders Rodrigo Ribeiro Rodrigues (CSO; PhD, Vanderbilt; Professor of Immunology, 30+ years) and Willians Dias (Electrical Engineering). To date, only $50,000 in equity funding (The Roux Institute, April 2023) and undisclosed grant amounts have been disclosed, and the product remains in investigational/pre-commercial status.

Name

Radiolife

Legal name

Radiolife

Website

https://radiolife.ai

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Radiolife is a pre-commercial diagnostics company that combines proprietary radiofrequency sensing with AI to deliver rapid, point-of-care disease detection for healthcare institutions, research organizations, underserved communities, and the veterinary/agricultural biosecurity market.

Ownership category

akta.pro rank

Product category

Diagnostic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

akta.pro secondary industries

Portable, Mobile & Point-of-Care Imaging Systems (HLAHABAL), Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), Imaging Equipment & Accessories (X-ray, Ultrasound, Endoscopy) (HLAMAFAC)

Keywords

• Diagnostic medical devices
• Radiofrequency diagnostics
• Point-of-care testing
• Veterinary diagnostics
• AI disease detection

Headquarters

HQ city

Wilmington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Diagnostic Device Sales: Sale of diagnostic medical devices including Cube Scan Vet for veterinary applications. The investigational diagnostic device aims to deliver fast, accurate, and cost-effective results.
2. Subscription Services: Newsletter subscription service mentioned at $10/month, suggesting a recurring revenue component for ongoing information and updates.
3. Licensing and Partnerships: Revenue potential through technology licensing to healthcare institutions, research organizations, and strategic partners who share the mission of revolutionizing diagnostics.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Core offering

Radiolife develops an investigational diagnostic medical device called Cube Scan that uses proprietary Radiofrequency (RF) technology combined with AI to deliver fast, accurate, and cost-effective point-of-care diagnostic results, such as Covid-19 diagnosis in 10 seconds. The platform also includes Cube Scan Vet for veterinary applications, including rapid on-site disease detection in poultry and livestock, and a real-time viral detection system demonstrated for HPAI (H5N1) monitoring.

Product overview

Radiolife offers a unified diagnostic platform centered on its Cube Scan device, which combines proprietary Radiofrequency (RF) technology with AI for rapid, accurate, and cost-effective diagnostics. The product portfolio includes the standard Cube Scan for human diagnostics (capable of Covid-19 diagnosis in 10 seconds) and Cube Scan Vet for veterinary applications. Both products leverage the same underlying RF + AI technology to deliver fast, accessible testing at the point of care.

Differentiator

Problem solved

Functional benefit

Brands

• Cube Scan Vet: A veterinary diagnostic product mentioned on the company's website for animal health diagnostics.

Products and services

• Cube Scan An investigational diagnostic medical device that uses proprietary Radiofrequency (RF) technology combined with AI to deliver fast, accurate, and cost-effective point-of-care diagnostic results for human healthcare applications.
• Cube Scan Vet A veterinary diagnostic device based on the Cube Scan platform, designed for animal health applications including rapid on-site disease detection in poultry and livestock.
• Real-time Viral Detection System A real-time viral detection system developed by Radiolife leveraging RF + AI for monitoring of H5N1 highly pathogenic avian influenza (HPAI) in poultry.

Quantifiable outcome

• Covid-19 diagnosis in 10 seconds
• +1 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core and supporting.

• The Roux Institute at Northeastern UniversitycoreStrategic or Co-development PartnerRadiolife was accepted into the Future of Healthcare Program at The Roux Institute. This partnership provides access to Northeastern University's healthcare innovation ecosystem, mentorship from industry leaders like Benjamin Chesler (Ecosystem Builder), and validation of their diagnostic technology potential. The partnership also includes participation in the Founder Residency program.
• NVIDIAsupportingTechnology or IntegrationRadiolife is a member of the NVIDIA Inception Program, which supports cutting-edge AI and deep-tech startups. This program provides access to NVIDIA resources, technical expertise, and GPU technology for AI development in diagnostics.
• Marketing EvolutionsupportingGTM or Marketing PartnerJohn Matthews, CRO at Marketing Evolution, has provided a testimonial endorsing Radiolife's technology and market potential. This represents a GTM partnership for market validation and potential referral relationships.
• Healthcare Institutions (General)supportingStrategic or Co-development PartnerRadiolife collaborates with healthcare institutions as partners who share their mission of revolutionizing diagnostics. The company actively seeks like-minded partners and investors for collaboration.
• Research Organizations (General)supportingStrategic or Co-development PartnerRadiolife partners with research organizations to advance pathology research and disease understanding using their RF technology and AI platform.
• Hello Tomorrow (Deep-Tech Pioneers)supportingGTM or Marketing PartnerRadiolife was recognized as a Deep-Tech Pioneer by Hello Tomorrow, a global organization dedicated to deep-tech innovation. This recognition provides visibility and access to the deep-tech ecosystem.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Cue Health: Cue Health developed a connected, rapid point-of-care diagnostic platform (with molecular test results in ~20 minutes) targeting consumers, healthcare institutions, and public health. It is directly comparable to Radiolife's Cube Scan as a hardware-based rapid POC diagnostics company aimed at decentralized testing.
• QuidelOrtho: QuidelOrtho manufactures rapid immunoassay and molecular diagnostic tests (e.g., Sofia platform, Sofia SARS Antigen FIA, Triage) widely used at the point of care in hospitals, urgent care, and physician offices - the same decentralized testing segments Radiolife targets.

Broad incumbents

• Abbott Diagnostics: Abbott's diagnostics arm sells the BinaxNOW, Panbio, and ID NOW rapid platforms, plus the Alinity core lab systems - the dominant incumbent offering in rapid POC infectious disease testing against which any new rapid diagnostic entrant must compete.
• Roche Diagnostics: Roche Diagnostics markets the cobas Liat and rapid antigen tests used at POC and centralized lab, as well as a broad IVD portfolio across infectious disease, cardiology, and oncology - the entrenched competitor with the deepest installed base in hospital diagnostics.
• Becton, Dickinson and Company (BD): BD's Diagnostic Solutions segment offers the BD Veritor rapid antigen system, BD MAX molecular platform, and a portfolio of point-of-care assays for hospitals and clinics - a broad incumbent in rapid POC diagnostics with strong distribution.
• IDEXX Laboratories: IDEXX is the leading specialty veterinary diagnostics company, providing in-clinic analyzers and reference lab services for companion animals and livestock. It is a direct comparable for Radiolife's Cube Scan Vet veterinary diagnostics business.
• Zoetis Diagnostics: Zoetis offers the Vetscan in-clinic diagnostic suite and reference lab services (via its acquisition of Abaxis and Phoenix Lab) for livestock biosecurity and companion animal care - competing with Cube Scan Vet in on-site animal disease detection.

Emerging players

• QuantuMDx: QuantuMDx is developing the Q-POC rapid molecular diagnostic device aimed at delivering lab-quality results in minutes at the point of care, including in resource-limited settings. It is an emerging peer in the same rapid POC hardware category as Radiolife's Cube Scan.
• T2 Biosystems: T2 Biosystems develops rapid direct-from-sample diagnostic devices (T2 Magnetic Resonance-based platforms) for sepsis and other bloodstream infections, with results in hours instead of days. It is an emerging peer using novel physics-based detection at the point of care.
• Binx Health: Binx Health offers the binx io molecular point-of-care platform for rapid chlamydia/gonorrhea testing in clinics and pharmacies. It is an emerging peer in rapid, decentralized molecular diagnostics targeting non-traditional testing sites - the same GTM thesis Radiolife pursues.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/radiolifelabs
• YouTubeyoutube.com/@radiolifelabs
• Facebookfacebook.com/radiolifelabs
• LinkedInlinkedin.com/company/radiolife
• Instagraminstagram.com/radiolifelabs

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Radiolife